Lviv clinical bulletin 2017, 1(17): 38-42

https://doi.org/10.25040/lkv2017.01.038

The Effectiveness of Rebamipide in Combined Treatment of Patients with Peptic Ulcer of the Stomach and Duodenum

Posted onAuthorAdminЗалишити коментар / Leave a comment

A. Demydova1, O. Sklyarova2, A. Chetaykina1

Danylo Halytsky Lviv National Medical University

1Department of Therapy N 1 and Medical Diagnostics FPGE

2Department of Family Medicine FPGE

Introduction. The place of rebamipide in treatment regimens of erosive and ulcerative Helicobacter pylori, associated with diseases of the stomach and duodenum, has not been fully investigated.

The aim of the study is to іnvestigate the effectiveness of rebamipide in treatment of patients with peptic ulcer of the stomach and duodenum.

Materials and methods. Were examined and treated 62 patients with peptic ulcer of the duodenum. The patients were divided into 2 groups depending on the treatment regimen. Patients of the first group (30 people) received conventional triple therapy: amoxicillin 1000.0 mg, clarithromycin 500.0 mg twice daily and omeprazole 20.0 mg twice daily for 10 days. The patients of the second groups (32 people) were additionally given rebamipide 100.0 mg three times a day for 10 days to conventional AHBT (amoxicillin 1000.0 mg, clarithromycin 500.0 mg twice daily and omeprazole 20.0 mg twice daily for 10 days).

The Statistical analysis of the results was performed on a PC using software packages license “Microsoft Excel 2007” (Microsoft), “Statistica® 6.0” (StatSoft Inc., USA).

Results of the investigation and their discussion. Thus the using of a standart AHBT was resulted to healing ulcers in 79.2 % of cases, the AHBT with the added rebamipide – in 85.2 %. The effectiveness at healing duodenal erosions in the treatment of a standart AHBT was 81.3%, AHBT with added rebamipide – 83.3 %.

Helicobacter pylori eradication occurred in 76.7 % of patients in the first group and in 81.3 % of patients in the second group. Adding rebamipide to AHBT has not significantly affected on eradication.

On the other hand, the epithelization of erosions and ulcers is took place against the background of the impact of such adverse factors as the presence of the signs of antral gastritis, esophagitis, duodenitis in a significant number of patients of both groups.

It was found the increased frequency of duodenitis at control esophagogastroduodenofibroscopy in the patients of the second group (p ˂ 0.01). Also marked increase in the frequency of the duodenogastal reflux (DGR) during the AHBT treatment with rebamipide at 30.0 % and standard AHBT at 88.9 %.

Conclusions. The positive aspects of combined treatment with the inclusion rebamipide are: relief of pain, a positive impact on the epithelization of erosions and ulcers of the stomach and duodenum, lower incidence of DGR after treatment. Among the negative points are reducing the frequency esophagitis and insufficiency of cardia in patients only at 25.0 %, and presence of duodenitis more than 60.0 % of patients after treatment.

References

  1. Bisyarin Y, Sklyarova O. Ultrastructure mucosa antrum in patients with peptic ulcer after antirecurrence treatment with the use of omeprazole and rebamipide. Acta Medica Leopoliensia. 2011;3:46-50. (Ukrainian).
  2. Vdovychenko V, Sklyarova O. Efficiency inclusion remedy “mukohen” to standard treatment regimens erosive and ulcerative diseases of the stomach and duodenum. Bukovina Medical Journal. 2011;2:196-198. (Ukrainian).
  3. Paly I, Vavrynchuk V, Salabai I, Zaika S. Modern requirements for the eradication of Helicobacter pylori in patients with erosive and ulcerative lesions of the stomach and duodenum. Modern Gastroenterol. 2010;4:111-119. (Ukrainian).
  4. Pasieshvili L. Peptіc ulcer and chronic gastritis: achievements and prospects. Modern Gastroenterology. 2009;4:94-99. (Russian).
  5. Perederiy V, Cherniavsky V, Sitnikov A. Proton pomp inhibitors 1 and 2nd generation, omeprazole and rabeprazole in the clinical practice – advantages and disadvantages. Medicine Today. 2006;5:20. (Russian).
  6. Perederiy V, Tkach S. Maastricht consensus IV – 2010: Basic situation and urgency for Ukraine. Modern Gastroenterol. 2011;6:133-136. (Ukrainian).
  7. Tkach S. Modern approaches for optimization infection therapy Helicobacter pylori. Modern Gastroenterol. 2012;5:83-90. (Ukrainian).
  8. Blaser MJ, Chen Yu, Reibman J. Helicobacter pylori – pro et contra? Gut. 2008;57:561-567. https://doi.org/10.1136/gut.2007.133462
  9. Mearin F, Ponce J. Potent acid inhibition: summary of the evidence and clinical application. Drugs. 2005;65(1 Suppl):113-126. https://doi.org/10.2165/00003495-200565001-00015
  10. Malfertheiner Bismuth improves PPIbased triple therapy for the H.pylori eradication. Nat Rev Gastroenterol Hepatol. 2010;7(10):538-539. https://doi.org/10.1038/nrgastro.2010.131